-
Alkem Laboratories Analyst Review 2027: Sales Up 14%, Profit Down 12%, and a Tax Rate That Tripled
- November 17, 2026
- Posted by: Kunal Singla
- Category: Market
No Comments
Alkem grew Q2 FY27 revenue 13.8% and EBITDA 11.3%, yet profit fell 11.7% as its tax rate jumped to 33%. We review five brokerage targets from ₹4,638 to ₹6,890, the India and export businesses, and the risks for 2027.
-
3 Engineering and Construction Major, Hospital Network and Pharma Company Stocks With a Strong Future Roadmap: Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories
- November 5, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Engineering, Hospital Chain and Pharma Stocks with a strong future roadmap: Larsen & Toubro, Krishna Institute of Medical Sciences and Alkem Laboratories. Compare price, valuation, return on equity and revenue growth as of 4 November 2026.
-
3 Global IT Services Company, Branded Pharmaceuticals Maker and Automotive Air Conditioning Systems Maker Stocks With a Strong Future Roadmap: Coforge, Alkem Laboratories and Subros
- November 4, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
IT Services, Branded Medicine and Car AC Stocks with a strong future roadmap: Coforge, Alkem Laboratories and Subros. Compare price, valuation, return on equity and revenue growth as of 3 November 2026.
-
3 US Generics Exporter, Anti-Infectives Franchise Owner and Biggest Indian Drug Maker by Value Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma
- October 29, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Generics, Anti-infective and Pharma Leader with a strong future roadmap: Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma. Compare price, valuation, return on equity and revenue growth as of 27 October 2026.
-
3 Anti-Infectives and Gastro Brands Leader, Research-Driven Pharma Company and Contract Formulations Producer Stocks With a Strong Future Roadmap: Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab
- October 27, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Acute Care Brand, Research and Contract Stocks with a strong future roadmap: Alkem Laboratories, Glenmark Pharmaceuticals and Innova Captab. Compare price, valuation, return on equity and revenue growth as of 26 October 2026.
-
3 Branded Generics Marketer, Anti-Infectives and Gastro Leader and Custom Synthesis Ingredients Leader Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Alkem Laboratories and Divi’s Laboratories
- October 27, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Branded Generics, Acute Care and API Stocks with a strong future roadmap: Emcure Pharmaceuticals, Alkem Laboratories and Divi’s Laboratories. Compare price, valuation, return on equity and revenue growth as of 26 October 2026.
-
3 Chronic Therapy Brands Company, Domestic Acute Care Leader and Active Ingredients Producer Stocks With a Strong Future Roadmap: Eris Lifesciences, Alkem Laboratories and Granules India
- October 26, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Chronic, Acute Care and Ingredient Pharma Stocks with a strong future roadmap: Eris Lifesciences, Alkem Laboratories and Granules India. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.
-
3 Specialty Pharma Maker, Global Generics Leader and Branded Medicines Company Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories
- October 26, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Branded Pharma and Specialty Generics Stocks with a strong future roadmap: JB Chemicals and Pharmaceuticals, Dr. Reddy’s Laboratories and Alkem Laboratories. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.
-
3 Anti-Infective and Gastro Franchise, Latin America Branded Generics and Respiratory Leader Stocks With a Strong Future Roadmap: Alkem Laboratories, Caplin Point Laboratories and Cipla
- October 23, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Branded Pharma and Emerging Market Stocks with a strong future roadmap: Alkem Laboratories, Caplin Point Laboratories and Cipla. Compare price, valuation, return on equity and revenue growth as of 22 October 2026.
-
3 Oncology Generics, Acute Therapy Franchise and Pain and Anti-Malarial Brands Stocks With a Strong Future Roadmap: Natco Pharma, Alkem Laboratories and Ipca Laboratories
- October 22, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Complex Generic and Pain Care Stocks with a strong future roadmap: Natco Pharma, Alkem Laboratories and Ipca Laboratories. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.